Abramenko I, Bilous N, Kryachok I, Filonenko I, Pilipenko G, Chumak A, Bazyka D, Bebeshko V
Scientific Centre for Radiation Medicine Academy of Medical Science of Ukraine, Kiev, Ukraine.
Exp Oncol. 2007 Sep;29(3):226-30.
THE AIM of the study was to evaluate the frequency of IGHV3-21 gene usage and its clinical significance for patients with B-cell chronic lymphocytic leukemia (CLL) in Ukraine.
Immunoglobulin variable heavy chain (IGHV) gene repertoire was studied in 189 CLL patients using reverse transcribed polymerase chain reaction and direct sequence of amplified products.
IGHV3-21 gene expression was found in 11 cases (5.8%), and its frequency was intermediate between Scandinavian (11.7%) and Mediterranean CLL (2.9%) cohorts. The most of cases (9 of 11) belonged to subset with heterogeneous HCDR3 (heteroHCDR3 subset), and only 2 cases--to subset with classical short ARDANGMDV motif (homHCDR3 subset). Six IGHV3-21 cases were mutated and 5 cases were unmutated. All unmutated cases (all were from heteroHCDR3 subset) had similarity of their HCDR3s with previously published sequences. The differences in overall (OS), progression-free (PFS) and treatment-free survival (TFS) for IGHV3-21 positive patients in comparison with CLL patients expressing the other IGHV genes were statistically insignificant. These survival parameters were comparable also for CLL patients with mutated IGHV3-21 gene usage and expression the others mutated IGHV genes. But remarkable feature of IGHV3-21 expressing patients was high incidence of solid tumors. They have developed in 4 IGHV3-21 positive cases (36.4%) and in 10 cases with expression of the others IGHV genes (5.6%, p=0.0002). Furthermore, in small group of 6 patients with mutated IGHV3-21 gene expression, 3 patients had solid tumors and one underwent Richter transformation. Unmutated IGHV3-21 gene expressed patients had worse OS and PFS in comparison with CLL patients that expressed the others unmutated IGHV genes.
Presented data are in agreement with the opinion about negative prognostic significance of IGHV3-21 gene expression regardless its mutation status. IGHV3-21 expression was associated with development of secondary solid tumors. Revealed high level of homology in heteroHDR3s subset might suggest about possible antigenic influence also, in addition to homHCDR3 subset that was proposed earlier.
本研究的目的是评估乌克兰B细胞慢性淋巴细胞白血病(CLL)患者IGHV3 - 21基因的使用频率及其临床意义。
采用逆转录聚合酶链反应和扩增产物直接测序技术,对189例CLL患者的免疫球蛋白可变重链(IGHV)基因库进行研究。
11例(5.8%)患者检测到IGHV3 - 21基因表达,其频率介于斯堪的纳维亚(11.7%)和地中海CLL(2.9%)队列之间。大多数病例(11例中的9例)属于具有异质性互补决定区3(heteroHCDR3亚组)的亚组,只有2例属于具有经典短ARDANGMDV基序的亚组(homHCDR3亚组)。6例IGHV3 - 21病例发生突变,5例未发生突变。所有未突变病例(均来自heteroHCDR3亚组)的互补决定区3与先前发表的序列具有相似性。与表达其他IGHV基因的CLL患者相比,IGHV3 - 21阳性患者的总生存期(OS)、无进展生存期(PFS)和无治疗生存期(TFS)差异无统计学意义。对于使用和表达突变IGHV3 - 21基因的CLL患者与表达其他突变IGHV基因者,这些生存参数也具有可比性。但IGHV3 - 21表达患者的显著特征是实体瘤发生率高。4例IGHV3 - 21阳性病例(36.4%)发生实体瘤,10例表达其他IGHV基因的病例发生实体瘤(5.6%,p = 0.0002)。此外,在6例IGHV3 - 21基因表达突变的小样本患者中,3例发生实体瘤,1例发生Richter转化。与表达其他未突变IGHV基因的CLL患者相比,未突变IGHV3 - 21基因表达患者的OS和PFS较差。
现有数据与关于IGHV3 - 21基因表达无论其突变状态均具有负面预后意义的观点一致。IGHV3 - 21表达与继发性实体瘤的发生有关。除了先前提出的homHCDR3亚组外,在heteroHDR3s亚组中发现的高水平同源性也可能提示可能的抗原影响。